Key result
Weight loss linked to ~2-point greater LVEF increase per 5% lost in dilated cardiomyopathy.
Why the study?
Baseline BMI and longitudinal weight change capture different clinical dimensions in dilated cardiomyopathy, but their concurrent associations with changes in LVEF, BNP, and NYHA class were unclear.
Does 12-month weight loss improve LVEF, BNP, and NYHA functional class in adults with dilated cardiomyopathy?
Cohort (n=322)
No
Does 12-month weight loss improve LVEF, BNP, and NYHA functional class in adults with dilated cardiomyopathy?
In patients with dilated cardiomyopathy, longitudinal 12-month weight loss, but not baseline BMI, is significantly associated with concurrent improvements in LVEF, BNP, and NYHA functional class, although the causality of this relationship remains ambiguous.
Answers are grounded in this paper and cite their sources.
May support weight loss monitoring in dilated cardiomyopathy; leaves open causality and need for prospective trials.
Background and Aims Baseline body mass index (BMI) and longitudinal weight change capture different clinical dimensions. We examined their concurrent associations with 12-month changes in left ventricular ejection fraction (LVEF), B-type natriuretic peptide (BNP), and New York Heart Association (NYHA) functional class among patients with dilated cardiomyopathy. Methods Of 600 records screened, 322 patients had complete paired baseline and 12-month measurements and were included in this retrospective cohort analysis. Percentage weight loss was calculated as 100 × (baseline weight−12-month weight)/baseline weight; negative values denoted weight gain. Joint models included baseline BMI and weight loss and adjusted for age, sex, log-transformed baseline BNP, baseline LVEF, left ventricular end-diastolic diameter, baseline NYHA class, diabetes, chronic kidney disease, atrial fibrillation, and coronary atherosclerosis. Results Thirty-six patients gained weight, six demonstrated no weight change, and 280 lost weight. Baseline BMI was not independently associated with LVEF change ( β = −0.099, 95% CI −0.269 to 0.071; P = 0.254), BNP log ratio ( β = 0.008, 95% CI −0.014 to 0.030; P = 0.467), or NYHA improvement (OR = 1.02, 95% CI 0.94–1.10; P = 0.709). Each 5% greater weight loss was concurrently associated with a greater increase in LVEF ( β = 2.43 percentage points, 95% CI 1.66–3.20), a lower BNP log ratio ( β = −0.317, 95% CI −0.415 to −0.219), and higher odds of NYHA improvement (OR = 1.93, 95% CI 1.38–2.74; all P < 0.001). The associations remained consistent after adjustment for the availability of heart-failure and weight-management therapies. Conclusions Twelve-month weight change was associated with concurrent changes in LVEF, BNP, and functional status, whereas baseline BMI was not. These data do not establish temporal direction, causality, or the superiority of weight change as a clinical marker.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) conducted a cohort in Dilated cardiomyopathy (n=322). 12-month weight loss vs. Lesser weight loss (evaluated per 5% increment) was evaluated on 12-month change in left ventricular ejection fraction (LVEF) (β = 2.43 percentage points, 95% CI 1.66-3.20, p=<0.001). Each 5% greater weight loss over 12 months was associated with a 2.43 percentage point increase in LVEF and higher odds of NYHA improvement in dilated cardiomyopathy, unlike baseline BMI.
Synapse has enriched 10 related papers. Consider them for comparative context: